NAD+
Nicotinamide adenine dinucleotide (NAD+) is an essential cellular coenzyme central to energy metabolism, redox reactions and multiple signaling pathways. The biology is foundational. The harder question is whether raising NAD+—with precursors or direct administration—reliably improves meaningful human outcomes.
NAD+ is essential to how your cells produce and manage energy, which is why supporting NAD+ biology has become such a major focus in energy, recovery and longevity.
NAD+ may be the clearest example yet of why BIOHACKING. EVOLVED. separates a compelling biological target from proof that an intervention improves healthspan.
●●○○○
Human studies of NAD+ precursors (particularly NR and NMN) are more extensive than trials of NAD+ administration itself. Raising NAD-related biomarkers does not establish meaningful anti-aging or performance benefits.
●●●●●
A deep rodent and laboratory literature links NAD biology to metabolism, mitochondria, inflammation and aging-related pathways.
●●●●●
NAD+ is a fundamental metabolic cofactor and substrate for enzymes involved in cellular signaling and repair.
●●●●●
High attention across longevity, energy, recovery, cognition and wellness—particularly IV and injectable NAD+.
A molecule at the center of cellular metabolism.
NAD+ participates in redox reactions that help cells convert nutrients into usable energy. It also serves as a substrate for enzymes involved in signaling, DNA-damage responses and metabolic regulation.
That makes NAD+ biologically important. It does not automatically mean that adding more NAD+—or raising it with a precursor—improves health in someone who is otherwise healthy.
Popular narrative. More nuanced human evidence.
The common story is simple: NAD+ declines with age, so restoring NAD+ should slow aging. A 2025 Nature Metabolism review found the human picture considerably more complicated. Age-related NAD+ decline has been consistently demonstrated in only a limited number of human studies, and tissue-specific human data remain sparse.
We can move the biomarker. Moving health outcomes is harder.
A 2026 PRISMA-guided systematic review identified 33 human intervention studies, including 28 randomized studies, across NAD-related compounds. Oral NR and NMN consistently demonstrated biochemical target engagement and were generally well tolerated over weeks to months.
But functional, metabolic, vascular and other healthspan-relevant outcomes were heterogeneous and frequently null or endpoint-specific. The review concluded that clinical effectiveness for anti-aging and wellness remains inconclusive.
These are related strategies—not interchangeable evidence.
NAD+ itself, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) should not be treated as one intervention. They differ in administration, absorption, metabolism and the amount and quality of human evidence behind them.
The 2026 systematic review found no eligible clinical-outcomes trials of IV or IM NAD+ itself for anti-aging or wellness. A small pharmacokinetic pilot showed that infused NAD+ changes NAD-related metabolism, but it was not an efficacy trial.
A 2026 retrospective commercial-setting pilot comparing IV NAD+ and IV NR reported more infusion-related gastrointestinal symptoms, increased heart rate and chest pressure with NAD+; the study was preliminary and not designed to establish anti-aging efficacy.
Where NAD+ gets overextended.
What people are actually reporting.
Recurring community-use patterns are visible around NAD+. We document those patterns here without turning them into a clinical recommendation.
Community discussions frequently describe 50–100 mg per injection, while both smaller and substantially larger amounts also appear. Route matters: IV infusion and subcutaneous or intramuscular use are not interchangeable exposure patterns.
There is no single clinically established NAD+ injection protocol for general “biohacking,” energy, longevity or recovery. NAD+ is an endogenous coenzyme, and clinical research varies by indication, route and formulation; community injection patterns should not be treated as a validated therapeutic regimen.
Direct injectable use adds a separate quality and safety question.
FDA has warned compounders about using food-grade NAD+ to make sterile IV products because ingredients intended for food use may present microbial and endotoxin contamination risks when used for sterile compounding. FDA has also reported adverse events after injectable NAD+ products, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment.
In a January 2026 warning letter to an outsourcing facility, FDA also stated that NAD+ did not appear on the 503B bulks list and, in that facility's circumstances, products compounded from NAD+ were not eligible for 503B exemptions.
NAD+ sits at the intersection of science and wellness culture.
Community discussion commonly links NAD+ with energy, recovery, mental clarity, longevity and “cellular rejuvenation.” The scientific foundation makes those narratives feel unusually intuitive—but the clinical evidence does not validate them equally.
MEANINGFUL
The gap depends on the claim. It is relatively narrow for NAD+ being fundamental to metabolism and for certain precursors increasing NAD-related biomarkers. It becomes much wider when the claim shifts to more energy, sharper cognition, faster recovery, slower aging or longer life.
This is exactly why NAD+ belongs in the Index: the underlying science is real, but the strength of the biology can make downstream wellness claims look more proven than they are.
Key sources behind the profile.
Follow the biology beyond peptides.
Longevity
Separate mechanisms associated with aging from demonstrated healthspan outcomes.
Metabolic Health
See how biomarkers, metabolism and meaningful clinical outcomes differ.
NAD+ evidence depends on the compound and route
What the published evidence supports—and what it does not.
This evidence check does not change the profile’s existing community-reporting content or constitute medical advice.